Factors associated with sclerostin levels – A calcification inhibitor – In individuals with type 2 diabetes mellitus; Is autonomic neuropathy the missing link?

Sclerostin inhibits bone formation and its expression is upregulated in the vasculature during the arterial calcification process as a counterregulatory mechanism preventing further calcification. Lower extremity arterial calcification (LEAC) is common in neuropathic patients with type 2 diabetes (T...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and its complications 2020-10, Vol.34 (10), p.107677-107677, Article 107677
Main Authors: Eleftheriadou, Ioanna, Tentolouris, Anastasios, Anastasiou, Ioanna A., Mourouzis, Iordanis, Tsilingiris, Dimitrios, Kosta, Ourania, Grigoropoulou, Pinelopi, Tentolouris, Nikolaos
Format: Article
Language:English
Subjects:
Angina pectoris
Ankle
Arterial calcification
Blood pressure
Calcification
Cardiac autonomic neuropathy
Cardiovascular disease
Coronary vessels
Creatinine
Diabetes
Diabetic neuropathy
Heart rate
Homeostasis
Peripheral neuropathy
Plasma
Regression analysis
Sclerostin
Statistical analysis
Type 2 diabetes mellitus
X-rays
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sclerostin inhibits bone formation and its expression is upregulated in the vasculature during the arterial calcification process as a counterregulatory mechanism preventing further calcification. Lower extremity arterial calcification (LEAC) is common in neuropathic patients with type 2 diabetes (T2DM). Herein, we investigated for associations between plasma sclerostin levels and diabetic neuropathy as well as LEAC in subjects with T2DM. A total of 74 individuals with and 76 without T2DMwere recruited. Plasma sclerostin levels were measured by ELISA. Diagnosis of cardiac autonomic neuropathy (CAN) was based on the battery of the four autonomic tests, while of somatosensory peripheral neuropathy (DPN) on neuropathy symptom score and neuropathy disability score. LEAC was assessed with conventional ankle and foot x-rays. Plasma sclerostin levels were higher in participants with LEAC vs. those without LEAC in both diabetes and non-diabetes cohorts (p = 0.035 and p = 0.003, respectively). In the diabetes cohort, patients with CAN, but not with DPN, had higher sclerostin levels when compared with those without CAN (p 
ISSN:1056-8727
1873-460X
DOI:10.1016/j.jdiacomp.2020.107677